Gender Differences in Discontinuation of Antiretroviral Treatment Regimens
- 1 November 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 52 (3), 336-341
- https://doi.org/10.1097/qai.0b013e3181b628be
Abstract
Reported reasons for change or discontinuation of antiretroviral therapy (δART) include adverse events, intolerability, and nonadherence. Little is known how reasons for δART differ by gender. In a retrospective cohort study, rates and reasons for δART alterations in a large University-based HIV clinic cohort were evaluated. Logistic regression analyses were used to evaluate the relationship between reasons for δART and gender. Cox proportional hazard models were used to investigate time to δART. In total, 631 HIV-positive individuals were analyzed. Women (n = 164) and men (n = 467) were equally likely (53.0% and 54.4%, respectively) to discontinue treatment within 12 month of initiating a new regimen. Reasons for δART, however, were different based on gender-women were more likely to δART due to poor adherence [adjusted odds ratio (OR), 1.44; 95% confidence interval (CI): 0.85 to 2.42], dermatologic symptoms (adjusted OR, 2.88; 95% CI: 1.01 to 8.18), neurological reasons (adjusted OR, 1.82; 95% CI: 0.98 to 3.39), constitutional symptoms (adjusted OR, 2.23; 95% CI: 1.10 to 4.51), and concurrent medical conditions (adjusted OR, 2.03; 95% CI: 1.00 to 4.12). Although the rates of δART are similar among men and women in clinical practice, the reasons for treatment changes are different based on gender. The potential for unique patterns of adverse events and poor adherence among women requires further investigation.Keywords
This publication has 24 references indexed in Scilit:
- Gender differences in the treatment of HIV infectionPharmacological Research, 2008
- Molecular epidemiology and prevalence of drug resistance-associated mutations in newly diagnosed HIV-1 patients in PortugalInfection, Genetics and Evolution, 2007
- Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infectionJournal of Antimicrobial Chemotherapy, 2007
- Patterns of primary antiretroviral drug resistance in antiretroviral-naive HIV-1-infected individuals in a midwest university clinicAIDS, 2006
- Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected personsJournal of Medical Virology, 2006
- Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV‐infected patient cohort*HIV Medicine, 2006
- Differences Between Women and Men in Adverse Events and CD4+ Responses to Nucleoside Analogue Therapy for HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Are There Gender Differences in Starting Protease Inhibitors, HAART, and Disease Progression Despite Equal Access to Care?JAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patientsAIDS, 2000
- Psychopathology in male and female HIV-positive and negative injecting drug usersAIDS, 1997